



Twist Bioscience Expands In Vivo Antibody Discovery Services with Launch of Humanized Transgenic Mouse Model

July 31, 2025

HuTg can be coupled with Twist hyperimmune DiversimAb mouse model and B cell screening methods

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Jul. 31, 2025-- [Twist Bioscience Corporation](#) (NASDAQ: TWST), a core mid-cap growth and value equity company in the life sciences segment of the health care sector, today announced the launch of a [humanized transgenic \(HuTg\) mouse model](#) to expand and complement its offering of antibody discovery services and further streamline monoclonal antibody discovery.

"The humanized transgenic mouse model complements our current in vivo antibody discovery platforms and can be paired with our DiversimAb mouse and B cell screening platforms, offering researchers multiple methods that can be used independently or together to generate more candidates with greater flexibility across varied disease areas," said Emily M. Leproust, CEO and co-founder of Twist Bioscience. "Typically, HuTg models require licensing from a provider but in contrast, Twist is offering a fee-for-service approach, working within customers' budgets and timelines by eliminating often time-consuming licensing negotiations."

The HuTg mouse model generates robust immune responses and human antibody repertoires to accelerate lead discovery and optimization. By using this platform, we enable Twist customers to identify fully human hits in weeks instead of months and streamlines translation into the clinic. This new offering expands and complements Twist's in vivo antibody discovery capabilities as it can be paired with Twist's DiversimAb mouse model to maximize epitope coverage and also paired with B cell screening platforms.

About Twist Bioscience Corporation

At Twist Bioscience, we work in service of customers who are changing the world for the better. In fields such as medicine, agriculture, industrial chemicals and defense, by using our synthetic DNA tools, our customers are developing ways to better lives and improve the sustainability of the planet. The faster our customers succeed, the better for all of us, and Twist Bioscience is uniquely positioned to help accelerate their efforts.

Our innovative silicon-based DNA Synthesis Platform provides precision at a scale that is otherwise unavailable to our customers. Our platform technologies overcome inefficiencies and enable cost-effective, rapid, precise, high-throughput synthesis, sequencing and therapeutics discovery, providing both the quality and quantity of the tools they need to most rapidly realize the opportunity ahead. For more information about our products and services, please visit www.twistbioscience.com.

Follow us on [LinkedIn](#) | [X](#) | [YouTube](#) | [Instagram](#) | [Bluesky](#)

Twist Bioscience Legal Notice Regarding Forward-Looking Statements

This press release contains forward-looking statements. All statements other than statements of historical facts contained herein are forward-looking statements reflecting the current beliefs and expectations of management made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, statements regarding the capabilities and benefits of new and expanded antibody discovery platforms and offerings. Forward-looking statements involve known and unknown risks, uncertainties, and other important factors that may cause Twist's actual results, performance, or achievements to be materially different from any future results, performance, or achievements expressed or implied by the forward-looking statements. Such risks and uncertainties include, among others, the ability to attract new customers and retain and grow sales from existing customers; the ability of Twist to achieve sufficient revenue to achieve or maintain positive cash flow from operations or profitability in any given period; ability to obtain financing when necessary; risks and uncertainties of rapidly changing technologies and extensive competition in synthetic biology that could make the products Twist is developing obsolete or non-competitive; ability to expand DNA synthesis manufacturing capacity; dependence on one supplier for a critical component; dependence on key personnel; additional regulations that could increase Twist's costs and delay commercialization efforts; changes in U.S. trade policies and other trade actions that could result in increased costs and supply chain disruptions; and the ability to maintain and enforce intellectual property protection. For a description of the risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to Twist's business in general, see Twist's risk factors set forth in Twist's Annual Report on Form 10-K for the year ended September 30, 2024 filed with the Securities and Exchange Commission (SEC) on November 18, 2024 and subsequent filings with the SEC. Any forward-looking statements contained in this press release speak only as of the date hereof, and Twist specifically disclaims any obligation to update any forward-looking statement, whether as a result of new information, future events or otherwise.

View source version on [businesswire.com](https://www.businesswire.com/news/home/20250731933170/en/): <https://www.businesswire.com/news/home/20250731933170/en/>

For Investors:

Angela Bitting
SVP, Corporate Affairs
925-202-6211
abitting@twistbioscience.com

For Media:

Amanda Houlihan

Communications Manager

774-265-5334

ahoulihan@twistbioscience.com

Source: Twist Bioscience Corporation